Niacin for Parkinson's disease

Marissa Seamon, Sharad Purohit, Banabihari Giri, Babak Baban, John Morgan, Raymond Chong, Chandramohan Wakade

Research output: Contribution to journalReview article

Abstract

Parkinson's disease (PD) is a neurodegenerative disease associated with progressive loss of motor function and cognitive decline occurring in 1% of the USA population. There is no cure for PD, and current treatment regimens are directed towards treating symptoms and not treating the underlying cause of the disease. Chronic neuroinflammation is associated with loss of neuronal cells, leading to motor and cognitive decline. Current clinical trials on drugs and nutraceuticals, such as coenzyme Q10 and niacin, are being carried out to delay progression and reduce damage by inflammatory molecules, such as reactive oxygen species and cytokines, in PD patients. In this review, we present available clinical trials and the role of niacin in reducing neuroinflammation in PD.

Original languageEnglish (US)
Pages (from-to)47-56
Number of pages10
JournalClinical and Experimental Neuroimmunology
Volume11
Issue number1
DOIs
StatePublished - Feb 1 2020

Fingerprint

Niacin
Parkinson Disease
coenzyme Q10
Clinical Trials
Dietary Supplements
Neurodegenerative Diseases
Reactive Oxygen Species
Cytokines
Pharmaceutical Preparations
Population
Cognitive Dysfunction
Therapeutics

Keywords

  • GPR109A
  • Parkinson's disease
  • microglia
  • neuroinflammation
  • niacin

ASJC Scopus subject areas

  • Neuroscience (miscellaneous)
  • Immunology
  • Immunology and Microbiology (miscellaneous)
  • Clinical Neurology

Cite this

Niacin for Parkinson's disease. / Seamon, Marissa; Purohit, Sharad; Giri, Banabihari; Baban, Babak; Morgan, John; Chong, Raymond; Wakade, Chandramohan.

In: Clinical and Experimental Neuroimmunology, Vol. 11, No. 1, 01.02.2020, p. 47-56.

Research output: Contribution to journalReview article

Seamon, Marissa ; Purohit, Sharad ; Giri, Banabihari ; Baban, Babak ; Morgan, John ; Chong, Raymond ; Wakade, Chandramohan. / Niacin for Parkinson's disease. In: Clinical and Experimental Neuroimmunology. 2020 ; Vol. 11, No. 1. pp. 47-56.
@article{aa28e174f90d4f5b893bf78279332c54,
title = "Niacin for Parkinson's disease",
abstract = "Parkinson's disease (PD) is a neurodegenerative disease associated with progressive loss of motor function and cognitive decline occurring in 1{\%} of the USA population. There is no cure for PD, and current treatment regimens are directed towards treating symptoms and not treating the underlying cause of the disease. Chronic neuroinflammation is associated with loss of neuronal cells, leading to motor and cognitive decline. Current clinical trials on drugs and nutraceuticals, such as coenzyme Q10 and niacin, are being carried out to delay progression and reduce damage by inflammatory molecules, such as reactive oxygen species and cytokines, in PD patients. In this review, we present available clinical trials and the role of niacin in reducing neuroinflammation in PD.",
keywords = "GPR109A, Parkinson's disease, microglia, neuroinflammation, niacin",
author = "Marissa Seamon and Sharad Purohit and Banabihari Giri and Babak Baban and John Morgan and Raymond Chong and Chandramohan Wakade",
year = "2020",
month = "2",
day = "1",
doi = "10.1111/cen3.12553",
language = "English (US)",
volume = "11",
pages = "47--56",
journal = "Clinical and Experimental Neuroimmunology",
issn = "1759-1961",
publisher = "John Wiley and Sons Ltd",
number = "1",

}

TY - JOUR

T1 - Niacin for Parkinson's disease

AU - Seamon, Marissa

AU - Purohit, Sharad

AU - Giri, Banabihari

AU - Baban, Babak

AU - Morgan, John

AU - Chong, Raymond

AU - Wakade, Chandramohan

PY - 2020/2/1

Y1 - 2020/2/1

N2 - Parkinson's disease (PD) is a neurodegenerative disease associated with progressive loss of motor function and cognitive decline occurring in 1% of the USA population. There is no cure for PD, and current treatment regimens are directed towards treating symptoms and not treating the underlying cause of the disease. Chronic neuroinflammation is associated with loss of neuronal cells, leading to motor and cognitive decline. Current clinical trials on drugs and nutraceuticals, such as coenzyme Q10 and niacin, are being carried out to delay progression and reduce damage by inflammatory molecules, such as reactive oxygen species and cytokines, in PD patients. In this review, we present available clinical trials and the role of niacin in reducing neuroinflammation in PD.

AB - Parkinson's disease (PD) is a neurodegenerative disease associated with progressive loss of motor function and cognitive decline occurring in 1% of the USA population. There is no cure for PD, and current treatment regimens are directed towards treating symptoms and not treating the underlying cause of the disease. Chronic neuroinflammation is associated with loss of neuronal cells, leading to motor and cognitive decline. Current clinical trials on drugs and nutraceuticals, such as coenzyme Q10 and niacin, are being carried out to delay progression and reduce damage by inflammatory molecules, such as reactive oxygen species and cytokines, in PD patients. In this review, we present available clinical trials and the role of niacin in reducing neuroinflammation in PD.

KW - GPR109A

KW - Parkinson's disease

KW - microglia

KW - neuroinflammation

KW - niacin

UR - http://www.scopus.com/inward/record.url?scp=85077379986&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85077379986&partnerID=8YFLogxK

U2 - 10.1111/cen3.12553

DO - 10.1111/cen3.12553

M3 - Review article

AN - SCOPUS:85077379986

VL - 11

SP - 47

EP - 56

JO - Clinical and Experimental Neuroimmunology

JF - Clinical and Experimental Neuroimmunology

SN - 1759-1961

IS - 1

ER -